EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells

Ashley V Huang, Yali Kong, Kan Wang, Milton L Brown, David Mu iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26167935 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ashley V Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Breast Neoplasms, Drug Discovery, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ryan Translational Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the most common cancers globally. Unfortunately, many patients with breast cancer develop resistance to chemotherapy and tumor recurrence, which is primarily driven by breast cancer stem cells (BCSCs). BCSCs behave like stem cells and can self-renew and differentiate into mature tumor cells, enabling the cancer to regrow and metastasize. Key markers like CD44 and aldehyde dehydrogenase-1 (ALDH1), along with pathways like Wingless-related integration site (Wnt), Notch, and Hedgehog, are critical to regulating this stem-like behavior of BCSCs and, thus, are being investigated as targets for various new therapies. This review summarizes marker-dependent strategies for targeting BCSCs and expands on the challenges for the development of anti-BCSC drugs. We explore cutting-edge approaches like artificial intelligence (AI)-driven drug discovery and urge readers to seriously consider biological clocks and chronotherapy as experimental variables in drug discovery. Collectively, the task of cancer researchers is to overcome the many hurdles targeting BCSCs if we hope to tangibly improve breast cancer treatment outcomes and reduce mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsBreast NeoplasmsDrug DiscoveryBiomarkers, TumorAntineoplastic AgentsHumansFemaleAnimalsAldehyde Dehydrogenase 1 FamilyHyaluronan Receptors

Stichwörter der Autor:innen

ALDH1DCLK-1breast cancer stem cellcircadian rhythmdrug discoveryinfradian rhythms

Substanzen

Biomarkers, TumorAntineoplastic AgentsAldehyde Dehydrogenase 1 FamilyHyaluronan Receptors

Autor:innen und Institutionen

  • Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA.
  • Department of Internal Medicine, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA.
  • Leroy T. Canoles Jr. Cancer Research Center, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA.

ORCID-Profile: David Mu

Förderung

  • Ryan Translational Research Fund

Zitieren

APA

Huang, A. V., Kong, Y., Wang, K., Brown, M. L., & Mu, D. (2025). Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167935

Vancouver

Huang AV, Kong Y, Wang K, Brown ML, Mu D. Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167935

BibTeX
@article{Huang2025,
  author = {Huang, Ashley V and Kong, Yali and Wang, Kan and Brown, Milton L and Mu, David},
  title = {Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26167935}
}
Kostenlos starten →